Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease PharmaTimesSubcutaneous delivery shows IVlevel efficacy in moderate to severe TEDClinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing ChangesNext: Kennedy changes vaccine panel charter after legal setback Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
